PHOTO
Bahrain on Wednesday approved the emergency use for regn-cov2 medicine, Regeneron Pharmaceuticals Inc’s and Roche's newly authorised Covid-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms, the state news agency (BNA) reported.
The report said updating the corona treatment protocol in the kingdom would reduce symptoms complications.
REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are drugs called “monoclonal antibodies”, that are designed to block viral attachment and entry into human cells to neutralise the virus.
REGN-COV2 also received emergency use approval from the US FDA to treat mild to moderate symptoms of Covid-19 in non-hospitalised adults and adolescents of 12 years of age and older, who weigh at least 40 kg, and for those who are at high risk for developing severe Covid symptoms or of hospitalisation.
Copyright © 2021 Khaleej Times. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
